Tissue Engineering and Regenerative Medicine

  • Vasif Hasirci
  • Nesrin Hasirci


Biomaterials and biomedical devices can be constructed of a variety of materials, and depending on the end use, incorporation of bioactive species such as drugs, enzymes, growth factors, and other molecules is possible. Until the last 15 years, a complete biological entity such as a cell was not incorporated into the biomedical devices. Most of these devices were generally expected and designed to be stable, to have service lives long enough to serve as long as the host lived, except for a few cases such as resorbable sutures and short-duration implants. However, the thought of biodegradable cell-seeded devices that would completely integrate with the biological system during the wound healing process was very appealing because these implants were to be designed to blend with the tissues in the body, and this would be a cure and would not leave behind any traces after a certain implantation period. As a result of these important advantages, this approach became a very appealing solution for many problems arising from the long-term implantation of durable materials. This new field, now called “tissue engineering,” is supported by a number of interdisciplinary fields (Fig. 18.1). The main components of tissue engineering are a scaffold or a cell carrier, mature or stem cells, and bioactive molecules such as growth factors (Fig. 18.2). Meanwhile cell therapies were introduced into the field of novel therapeutic tools where the main difference from tissue engineering was the absence of the scaffold. Over time these two fields together started to be called regenerative medicine.


  1. 1.
    Bahcecioglu G (2018) PhD Thesis, Middle East Technical University, Department of BiotechnologyGoogle Scholar
  2. 2.
    Langer R, Vacanti JP (1993) Tissue engineering. Science 260(5110):920–926CrossRefGoogle Scholar
  3. 3.
  4. 4.
    Yilgor P (2009) Sequential growth factor delivery from polymeric scaffolds for bone tissue engineering. PhD Thesis, Middle East Technical University, AnkaraGoogle Scholar
  5. 5.
    Alagoz AS (2016) Bone tissue engineering using Macroporous PHBV-ELP Scaffolds. PhD Thesis, Middle East Technical University, AnkaraGoogle Scholar
  6. 6.
    Karadas O (2011) Collagen scaffolds with in situ grown calcium phosphate for Osteogenic differention of Wharton’s jelly and menstrual blood stem cells. MSc Thesis, Middle East Technical University, AnkaraGoogle Scholar
  7. 7.
    Ndreu A (2007) Electrospun Nanofibrous scaffolds for tissue engineering. MSc Thesis, Middle East Technical University, AnkaraGoogle Scholar
  8. 8.
    Zorlutuna P (2005) Cornea Engineering on biodegradable polymers. MSc Thesis, Middle East Technical Universtiy, AnkaraGoogle Scholar
  9. 9.
    Courtesy of V. Hasirci Lab.Google Scholar
  10. 10.
    Kenar H (2008) PhD thesis, Middle East Technical UniversityGoogle Scholar
  11. 11.
    Vrana E (2007) Development of collagen scaffolds for cornea engineering. MSc Thesis, Middle East Technical University, AnkaraGoogle Scholar
  12. 12.
    Chen QZ, Thompson ID, Boccaccini AR (2006) 45S5 Bioglass-derived glass-ceramic scaffolds for bone tissue engineering. Biomaterials 27(11):2414–2425CrossRefGoogle Scholar
  13. 13.
    Cheng M-q et al (2016) A novel open-porous magnesium scaffold with controllable microstructures and properties for bone regeneration. Sci Rep 6:24134CrossRefGoogle Scholar
  14. 14.
    Reddy CSK, Ghai R, Rashmi VCK (2003) Polyhydroxyalkanoates: an overview. Bioresour Technol 87:137–146CrossRefGoogle Scholar
  15. 15.
    Fröhlich M et al (2010) Bone grafts engineered from human adipose-derived stem cells in perfusion bioreactor culture. Tissue Eng Part A 16(1):179–189CrossRefGoogle Scholar
  16. 16.
    Bondioli E et al (2014) Development and evaluation of a decellularized membrane from human dermis. J Tissue Eng Regen Med 8(4):325–336CrossRefGoogle Scholar
  17. 17.
    Dowling DP, Miller IS, Ardhaoui M, Gallagher WM (2011) Effect of surface wettability and topography on the adhesion of osteosarcoma cells on plasma-modified polystyrene. J Biomater Appl 26:327–347CrossRefGoogle Scholar
  18. 18.
    Kim SH et al (2007) Correlation of proliferation, morphology and biological responses of fibroblasts on LDPE with different surface wettability. J Biomater Sci Polym Ed 18(5):609–622CrossRefGoogle Scholar
  19. 19.
    Ruoslahti E (1996) RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12:697–715CrossRefGoogle Scholar
  20. 20.
    Tashiro K et al (1989) A synthetic peptide containing the IKVAV sequence from the A chain of laminin mediates cell attachment, migration, and neurite outgrowth. J Biol Chem 264(27):16174–11618Google Scholar
  21. 21.
    Kenar H (2003) In vitro bone tissue engineering on patterned biodegradable polyester blends. MSc Thesis, Middle East Technical University, AnkaraGoogle Scholar
  22. 22.
    Martin I et al (2012) The survey on cellular and engineered tissue therapies in Europe in 2010. Tissue Eng Part A 18:21–22CrossRefGoogle Scholar
  23. 23.
    The European Agency for the Evaluation of Medicinal Products (EMEA); Evaluation of Medicines for Human use: Points to consider on xenogeneic cell therapy medicinal products, 17.12.2002, (CPMP/1199/02).
  24. 24.
    Verfaillie CM (2002) Adult stem cells: assessing the case for pluripotency. Trends Cell Biol 12(11):502–508CrossRefGoogle Scholar
  25. 25.
    Gnecchi M, Melo LG (2008) Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. Methods Mol Biol 482:281–294CrossRefGoogle Scholar
  26. 26.
  27. 27.
    Sofroniew MV, Howe CL, Mobley WC (2001) Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24:1217–1281CrossRefGoogle Scholar
  28. 28.
  29. 29.
    Chen RR, Mooney DJ (2003) Polymeric growth factor delivery strategies for tissue engineering. Pharm Res 20(8):1103–1112CrossRefGoogle Scholar
  30. 30.
  31. 31.
    Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363(9418):1346–1353CrossRefGoogle Scholar
  32. 32.
    Linkhart TA, Mohan S, Baylink DJ (1996) Growth factors for bone growth and repair: IGF, TGF beta and BMP. Bone 19(1 Suppl):1S–12SCrossRefGoogle Scholar
  33. 33.
    Goodsell DS (2003) The molecular perspective: epidermal growth factor. Oncologist 8(5):496–497CrossRefGoogle Scholar
  34. 34.
    Yun Y-R, Won JE, Jeon E, Lee S, Kang W et al (2010) Fibroblast growth factors: biology, function, and application for tissue regeneration. J Tissue Eng. Scholar
  35. 35.
    Kim B, Huang G, Ho WB, Greenspan DS (2011) Bone morphogenetic protein-1 processes insulin-like growth factor-binding protein 3. J Biol Chem 286(33):29014–29025CrossRefGoogle Scholar
  36. 36.
  37. 37.
    (2001) BMC Cell Biol 2:14Google Scholar
  38. 38.
    Daluiski A, Engstrand T, Bahamonde ME, Gamer LW, Agius E, Stevenson SL, Cox K, Rosen V, Lyons KM (2001) Bone morphogenetic protein-3 is a negative regulator of bone density. Nat Genet 27:84–88CrossRefGoogle Scholar
  39. 39.
    Reddi AH (1994) Symbiosis of biotechnology and biomaterials: applications in tissue engineering of bone and cartilage. J Cell Biochem 56:192–195CrossRefGoogle Scholar
  40. 40.
    Sadlon TJ, Lewis ID, D’Andrea RJ (2004) BMP4: its role in development of the hematopoietic system and potential as a hematopoietic growth factor. Stem Cells 22(4):457–474CrossRefGoogle Scholar
  41. 41.
    Chang SC, Hoang B, Thomas JT, Vukicevic S, Luyten FP, Ryba NJ, Kozak CA, Reddi AH, Moos M Jr (1994) Cartilage-derived morphogenetic proteins. New members of the transforming growth factor-beta superfamily predominantly expressed in long bones during human embryonic development. J Biol Chem 269:28227–28234Google Scholar
  42. 42.
    Indrawattana N, Chen G, Tadokoro M, Shann LH, Ohgushi H, Tateishi T, Tanaka J, Bunyaratvej A (2004) Growth factor combination for chondrogenic induction from human mesenchymal stem cell. Biochem Biophys Res Commun 320:914–919CrossRefGoogle Scholar
  43. 43.
    Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ, Attisano L (2003) Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol 23(20):7230–7242CrossRefGoogle Scholar
  44. 44.
    Cheifetz S, Li IW, McCulloch CA, Sampath K, Sodek J (1996) Influence of osteogenic protein-1 (OP-1;BMP-7) and transforming growth factorbeta 1 on bone formation in vitro. Connect Tissue Res 35(1–4):71–78CrossRefGoogle Scholar
  45. 45.
    Majumdar MK, Wang E, Morris EA (2001) BMP-2 and BMP-9 promotes chondrogenic differentiation of human multipotential mesenchymal cells and overcomes the inhibitory effect of IL-1. J Cell Physiol 189(3):275–284CrossRefGoogle Scholar
  46. 46.
    Gallucci RM, Simeonova PP, Toriumi W, Luster MI (2000) TNF-alpha regulates transforming growth factor-alpha expression in regenerating murine liver and isolated hepatocytes. J Immunol 164:872–878CrossRefGoogle Scholar
  47. 47.
    Ikada Y (1999) Key factors in tissue engineering. Bull Mater Sci 22(3):627–631CrossRefGoogle Scholar
  48. 48.
    Matsumoto Y et al (2012) Bone morphogenetic protein-3b (BMP-3b) inhibits osteoblast differentiation via Smad2/3 pathway by counteracting Smad1/5/8 signaling. Mol Cell Endocrinol 350:78–86CrossRefGoogle Scholar
  49. 49.
    Hsiong SX, Mooney DJ (2006) Regeneration of vascularized bone. Periodontol 2000 41:109–122CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Vasif Hasirci
    • 1
  • Nesrin Hasirci
    • 2
  1. 1.BIOMATEN Center of Excellence in Biomaterials and Tissue Engineering, and Department of Biological SciencesMiddle East Technical UniversityAnkaraTurkey
  2. 2.BIOMATEN Center of Excellence in Biomaterials and Tissue Engineering, and Department of ChemistryMiddle East Technical UniversityAnkaraTurkey

Personalised recommendations